File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: HT1001, proprietary north american ginseng extract, improves working memory in schizophrenia: Double-blind, placebo-controlled study

TitleHT1001, proprietary north american ginseng extract, improves working memory in schizophrenia: Double-blind, placebo-controlled study
Authors
Keywordscognitive function
HT1001
North American ginseng extract
schizophrenia
working memory
Issue Date2012
PublisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/12567
Citation
Phytotherapy Research, 2012, v. 26 n. 8, p. 1166-1172 How to Cite?
AbstractEvidence suggests that HT1001™, proprietary North American ginseng extract containing known levels of active ginsenosides, may improve cognitive function. Importantly, individuals with schizophreni show marked deficits in working memory, which are believed to be predictive of functional outcome in this population. The present study aimed to characterize the effect of HT1001 on working memory in group of stable individuals with schizophrenia. In double-blind, placebo-controlled study design, total of 64 individuals satisfying DSM-IV criteri for schizophreni were randomly assigned to receive either HT100 or placebo for 4 weeks. Verbal working memory and visual working memory were assessed at baseline and again at the end of the treatment phase using the Letter-Number Span Test and Visual Pattern Test, respectively. Symptoms and medication side effects were also measured at baseline and post-treatment. Visual working memory was significantly improved in the HT1001 group, but not in the placebo group. Furthermore, extrapyramidal symptoms were significantly reduced after 4 weeks treatment with HT1001, whereas no difference in extrapyramidal effects was observed in the placebo group. These results provide solid foundation for the further investigation of HT1001 as an adjunct therapy in schizophrenia, as an improvement in working memory and reduction in medication-related side effects has considerable potential to improve functional outcome in this population. Copyright © 2011 John Wiley & Sons, Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/146907
ISSN
2015 Impact Factor: 2.694
2015 SCImago Journal Rankings: 0.842
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChen, EYHen_HK
dc.contributor.authorHui, CLMen_HK
dc.date.accessioned2012-05-23T05:49:17Z-
dc.date.available2012-05-23T05:49:17Z-
dc.date.issued2012en_HK
dc.identifier.citationPhytotherapy Research, 2012, v. 26 n. 8, p. 1166-1172en_HK
dc.identifier.issn0951-418Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/146907-
dc.description.abstractEvidence suggests that HT1001™, proprietary North American ginseng extract containing known levels of active ginsenosides, may improve cognitive function. Importantly, individuals with schizophreni show marked deficits in working memory, which are believed to be predictive of functional outcome in this population. The present study aimed to characterize the effect of HT1001 on working memory in group of stable individuals with schizophrenia. In double-blind, placebo-controlled study design, total of 64 individuals satisfying DSM-IV criteri for schizophreni were randomly assigned to receive either HT100 or placebo for 4 weeks. Verbal working memory and visual working memory were assessed at baseline and again at the end of the treatment phase using the Letter-Number Span Test and Visual Pattern Test, respectively. Symptoms and medication side effects were also measured at baseline and post-treatment. Visual working memory was significantly improved in the HT1001 group, but not in the placebo group. Furthermore, extrapyramidal symptoms were significantly reduced after 4 weeks treatment with HT1001, whereas no difference in extrapyramidal effects was observed in the placebo group. These results provide solid foundation for the further investigation of HT1001 as an adjunct therapy in schizophrenia, as an improvement in working memory and reduction in medication-related side effects has considerable potential to improve functional outcome in this population. Copyright © 2011 John Wiley & Sons, Ltd.en_HK
dc.languageengen_US
dc.publisherJohn Wiley & Sons Ltd. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/12567en_HK
dc.relation.ispartofPhytotherapy Researchen_HK
dc.rightsPhytotherapy Research. Copyright © John Wiley & Sons Ltd.-
dc.subjectcognitive functionen_HK
dc.subjectHT1001en_HK
dc.subjectNorth American ginseng extracten_HK
dc.subjectschizophreniaen_HK
dc.subjectworking memoryen_HK
dc.titleHT1001, proprietary north american ginseng extract, improves working memory in schizophrenia: Double-blind, placebo-controlled studyen_HK
dc.typeArticleen_HK
dc.identifier.emailChen, EYH: eyhchen@hku.hken_HK
dc.identifier.authorityChen, EYH=rp00392en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/ptr.3700en_HK
dc.identifier.pmid22213250-
dc.identifier.scopuseid_2-s2.0-84864288964en_HK
dc.identifier.hkuros199754en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-84864288964&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume26en_HK
dc.identifier.issue8en_HK
dc.identifier.spage1166en_HK
dc.identifier.epage1172en_HK
dc.identifier.isiWOS:000306685900009-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridChen, EYH=7402315729en_HK
dc.identifier.scopusauthoridHui, CLM=35734149500en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats